ATE319840T1 - Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia - Google Patents

Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia

Info

Publication number
ATE319840T1
ATE319840T1 AT98962932T AT98962932T ATE319840T1 AT E319840 T1 ATE319840 T1 AT E319840T1 AT 98962932 T AT98962932 T AT 98962932T AT 98962932 T AT98962932 T AT 98962932T AT E319840 T1 ATE319840 T1 AT E319840T1
Authority
AT
Austria
Prior art keywords
expression system
restin
endostatin
angiostatin
producing anti
Prior art date
Application number
AT98962932T
Other languages
English (en)
Inventor
Vikas P Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE319840T1 publication Critical patent/ATE319840T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
AT98962932T 1997-12-08 1998-12-08 Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia ATE319840T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6788897P 1997-12-08 1997-12-08
US8266398P 1998-04-22 1998-04-22
US10853698P 1998-11-16 1998-11-16

Publications (1)

Publication Number Publication Date
ATE319840T1 true ATE319840T1 (de) 2006-03-15

Family

ID=27371250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962932T ATE319840T1 (de) 1997-12-08 1998-12-08 Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia

Country Status (10)

Country Link
EP (3) EP1038011B1 (de)
JP (3) JP2002503449A (de)
KR (3) KR20010015867A (de)
CN (3) CN1284134A (de)
AT (1) ATE319840T1 (de)
AU (3) AU749904B2 (de)
CA (3) CA2312287A1 (de)
DE (1) DE69833794D1 (de)
IL (3) IL136665A0 (de)
WO (3) WO1999029855A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852691B1 (en) 1997-12-08 2005-02-08 Beth Israel Deaconess Medical Center Anti-angiogenic peptides and methods of use thereof
IL136665A0 (en) * 1997-12-08 2001-06-14 Beth Israel Hospital Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO2000017240A1 (de) * 1998-09-21 2000-03-30 Haemopep Pharma Gmbh Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
JP2001031586A (ja) * 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
EP1246642B1 (de) * 1999-12-30 2005-09-07 Aventis Pharma S.A. Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
JP2004500087A (ja) * 2000-02-10 2004-01-08 ザイモジェネティクス，インコーポレイティド 抗−脈管形成性腸ペプチド、ｚｄｉｎｔ５
CN1311228A (zh) * 2000-03-02 2001-09-05 上海博德基因开发有限公司 一种新的多肽——人精子特异蛋白em1,em6－48和编码这种多肽的多核苷酸
EP1666595A1 (de) 2000-10-26 2006-06-07 Beth Israel Deaconess Medical Center, Inc. P97 (GAB2) Gen, und Verfahren zu dessen Verwendung
KR100579660B1 (ko) * 2003-08-18 2006-05-15 정인식 제미니바이러스 발현시스템을 이용한 재조합 신생혈관생성억제 단백질의 제조방법
DE602004017487D1 (de) 2003-08-29 2008-12-11 Childrens Medical Center Antiangiogene peptide vom n-terminus von endostatin
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
EP2270055A4 (de) * 2008-04-04 2011-06-29 Procell Therapeutics Inc Zellpermeables rekombinantes endostatinprotein, polynukleotid zu dessen kodierung und antikrebspräparat mit dem protein als wirkstoff
RU2014113924A (ru) * 2011-09-09 2015-10-20 Тсинхуа Юниверсити Мутанты эндостатина с мутациями в сайтах связывания атф
EP2628748A1 (de) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin-Chimäre und deren Verwendungen
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
JP6952685B2 (ja) 2015-06-05 2021-10-20 アイバイオ・インコーポレイテッドＩｂｉｏ， Ｉｎｃ． 線維症の治療において使用するためのエンドスタチン断片およびバリアント
CN115216513A (zh) * 2022-07-19 2022-10-21 广东赤萌医疗科技有限公司 一种检测细胞迁移能力的方法
CN119798415A (zh) * 2024-12-31 2025-04-11 西安巨子生物基因技术股份有限公司 一种新的重组人xv型胶原蛋白、其生产方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
HUT76095A (en) * 1994-04-26 1997-06-30 Childrens Medical Center Angiostatin and method of use for inhibition of angiogenesis
WO1996035774A2 (en) * 1995-04-26 1996-11-14 The Children's Medical Center Corporation Angiostatin fragments and aggregate angiostatin and methods of use
BR9611174A (pt) * 1995-10-23 1999-09-14 Childrens Medical Center Proteína de endostatina isolada, e composições terapêuticas antiangiogénicas formadas com a mesma.
WO1999016889A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
AU1598599A (en) * 1997-11-20 1999-06-15 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
IL136665A0 (en) * 1997-12-08 2001-06-14 Beth Israel Hospital Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof

Also Published As

Publication number Publication date
EP1037985A1 (de) 2000-09-27
WO1999029856A1 (en) 1999-06-17
EP1038011B1 (de) 2006-03-08
WO1999029878A2 (en) 1999-06-17
AU1718099A (en) 1999-06-28
WO1999029855A1 (en) 1999-06-17
AU1808899A (en) 1999-06-28
IL136667A0 (en) 2001-06-14
CN1322246A (zh) 2001-11-14
JP2002503449A (ja) 2002-02-05
AU753889B2 (en) 2002-10-31
CA2313251A1 (en) 1999-06-17
IL136668A0 (en) 2001-06-14
DE69833794D1 (de) 2006-05-04
JP2001526031A (ja) 2001-12-18
KR20010015867A (ko) 2001-02-26
IL136665A0 (en) 2001-06-14
JP2001526040A (ja) 2001-12-18
CA2313705A1 (en) 1999-06-17
CN1284134A (zh) 2001-02-14
AU1806599A (en) 1999-06-28
EP1038011A2 (de) 2000-09-27
KR20010015868A (ko) 2001-02-26
CN1284130A (zh) 2001-02-14
KR20010015869A (ko) 2001-02-26
AU742866B2 (en) 2002-01-17
CA2312287A1 (en) 1999-06-17
AU749904B2 (en) 2002-07-04
EP1037983A1 (de) 2000-09-27
WO1999029878A3 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
DE69833794D1 (de) Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
ATE435292T1 (de) Thermophiles expressionssystem in pilzen
DK0839006T4 (da) Fremgangsmåde til stabilisering af proteiner i et surt miljø med et højester-pectin
DE69527835D1 (de) Methode zur herstellung einer variante eines lipolytischen enzymes
PT1204738E (pt) Processo para a diminuicao da formacao de espuma durante a cultura de um microrganismo
DE69939945D1 (de) Verfahren zur isolierung von stammzellen
ATE203270T1 (de) Verfahren für die herstellung von proteinen
DE69711629D1 (de) Verfahren zur herstellung von polyol-fettsäure-polyestern unter verwendung atmosphärischen oder überatmosphärischen drucks
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
DE60011390D1 (de) Verfahren und vorrichtung zur identifikation oder karakterisierung von polypeptiden
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE59701603D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
DE59710925D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen
ATE292686T1 (de) Herstellung von nisin-varianten
DE58905117D1 (de) Verfahren zur herstellung von 4-chlor-2,5-dimethoxyanilin.
DE3575743D1 (de) Verfahren zur gewinnung von phenylalanin-dehydrogenase enthaltenden mikroorganismen und deren verwendung zur herstellung von l-alpha-aminosaeuren.
DE59606567D1 (de) Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-Alpha-Aminosäuren
DE69613811D1 (de) Methode und System zur Erzeugung und Verwendung von Brenngasen, insbesondere Gasen hergestellt aus Biomassen und Abfall
ATE349529T1 (de) Hyphenwachstum in pilzen
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
DK1129206T3 (da) Fremgangsmåde til nedbrydning af fermenterings-restmaterialer
ATE515947T1 (de) Verfahren zur herstellung von abgeschwächten starterkulturen
UA32437C2 (uk) Спосіб здійснення експресії амінопептидазного антигену н110д

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties